Fate Therapeutics (F6T) Price & Analysis

1 Followers

F6T Stock Chart & Stats

€2.14

-€0.03(-1.29%)

At close: Jul 24 4:00 PM EDT

€2.14

-€0.03(-1.29%)

Day’s Range― - ―

52-Week Range€0.76 - €2.67

Previous CloseN/A

Volume0.00

Average Volume (3M)13.00

Market Cap

€247.62M

Enterprise Value€46.00

Total Cash (Recent Filing)€174.82M

Total Debt (Recent Filing)€76.78M

Price to Earnings (P/E)―

Beta1.58

Next Earnings

Aug 05, 2026

EPS Estimate

-0.23

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.09

Shares Outstanding116,559,190

10 Day Avg. Volume40

30 Day Avg. Volume13

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)0.56

Price to Sales (P/S)17.56

P/FCF Ratio-1.04

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€4.55

Price Target Upside112.80% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering9

EPS Forecast (FY)-0.95

Revenue Forecast (FY)€4.62M

Bulls Say, Bears Say

Bulls Say

IPSC Off-the-shelf Cell Therapy PlatformFate’s iPSC-based, off-the-shelf approach is a durable competitive asset: scalable manufacturing and multiple next‑gen candidates create the potential for lower-cost, outpatient-enabled cell therapies across autoimmune and oncology indications, supporting repeatable commercial supply if clinical success is achieved.

Shareholder And Governance SupportRecent shareholder votes signal backing for the board, auditor, and incentive plan; governance continuity and sanctioned equity incentives improve management retention and alignment, increasing the likelihood of sustained focus and execution of multi-year clinical and commercialization plans.

Manageable Leverage And Positive EquityRelative to many late‑stage biotechs, Fate’s debt load appears moderate versus equity, providing some financial flexibility. A manageable capital structure helps preserve options for structured financings or partnerships to fund development without immediate insolvency risk, assuming burn is addressed.

Bears Say

High Cash Burn And Negative Operating Cash FlowSustained ~-$100M annual cash burn creates persistent financing needs and raises dilution risk; this constrains strategic optionality, pressures management to secure external capital or partnerships, and can impair long‑term program continuity if capital markets tighten.

Small, Declining Revenue And Negative Gross ProfitWith negligible and falling revenue plus negative gross margins, Fate lacks a commercial revenue base to offset development costs. This structural weakness means long-term viability depends on clinical progress or external funding rather than operating cash generation.

Shrinking Equity Base From Sustained LossesA markedly reduced equity cushion over several years reflects accumulated losses and potential dilution. Eroding equity limits balance-sheet resilience, raises cost of capital, and reduces the company’s ability to absorb setbacks or pursue large-scale commercialization without significant external funding.

Fate Therapeutics News

Fate Therapeutics announces FDA clearance of FT839 IND application

Fate Therapeutics (FATE) announced that the FDA has cleared its investigational new drug, or IND, application for FT839,...

26d ago

FATE

FATE Upcoming Earnings Report: What to Expect?

Fate Therapeutics Inc (FATE) is scheduled to report 2nd quarter earnings on 08/05/2026. Regarding Q2 estimates, Wall Street...

2d ago

FATE

Fate Therapeutics: FT839 Advancement and Autoimmune Potential Underpin Buy Rating, 12-Month $7 Price Target Reaffirmed

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Fate Therapeutics, with...

26d ago

FATE

Fate Therapeutics Shareholders Back Directors and Governance Plans

An announcement from Fate Therapeutics ( ($FATE) ) is now available. At its annual meeting of stockholders held...

2M ago

FATE

Fate Therapeutics Advances Off-the-Shelf CAR-T Autoimmune Pipeline

Fate Therapeutics ( ($FATE) ) has shared an announcement. On June 4, 2026, Fate Therapeutics updated its corporate...

2M ago

FATE

Gil Blum Reiterates Hold on Fate Therapeutics as Early FT819 Data Show Promise but Uncertain Durability

Needham analyst Gil Blum has maintained their neutral stance on FATE stock, giving a Hold rating on May...

2M ago

FATE

Fate Therapeutics management to meet with Piper Sandler

Meeting to be held on June 8 hosted by Piper Sandler. Published first on TheFly – the ultimate...

2M ago

FATE

5 Healthcare Stocks Set to Join the Russell 3000

FTSE Russell has released its preliminary changes for the Russell 3000 Index ahead of the official rebalancing on...

2M ago

QSI

AGEN

CTXR, AMT, JAZZ, CTMX, FATE Trending With Analysts

Analysts are intrested in these 5 stocks: ( ($CTXR) ), ( ($AMT) ), ( ($JAZZ) ), ( ($CTMX)...

2M ago

AMT

CTMX

Fate Therapeutics price target raised to $2.20 from $2 at BofA

BofA raised the firm’s price target on Fate Therapeutics (FATE) to $2.20 from $2 and keeps a Neutral...

2M ago

FATE

Fate Therapeutics assumed with a Buy at Jefferies

Jefferies assumed coverage of Fate Therapeutics (FATE) with a Buy rating and $4 price target Lead program FAT819...

3M ago

FATE

Gil Blum Maintains Hold Rating Amid Uncertainty on FT819 Durability and Rising Competition in Lupus Nephritis Cell Therapies

Needham analyst Gil Blum has maintained their neutral stance on FATE stock, giving a Hold rating today. Gil...

3M ago

FATE

Tara Bancroft Reiterates Hold Rating as FT819’s Autoimmune Momentum Offsets Early-Stage, Regulatory and Execution Risks

TD Cowen analyst Tara Bancroft has maintained their neutral stance on FATE stock, giving a Hold rating today....

3M ago

FATE

Fate Therapeutics reports Q1 EPS (26c), consensus (28c)

Reports Q1 revenue $1.3M, consensus $1.55M. “We are incredibly excited and focused on initiating RECLAIM-LN, our Phase 2...

3M ago

FATE

F6T FAQ

What was Fate Therapeutics Inc’s price range in the past 12 months?

Fate Therapeutics Inc lowest stock price was €0.76 and its highest was €2.67 in the past 12 months.

What is Fate Therapeutics Inc’s market cap?

Fate Therapeutics Inc’s market cap is €247.62M.

When is Fate Therapeutics Inc’s upcoming earnings report date?

Fate Therapeutics Inc’s upcoming earnings report date is Aug 05, 2026 which is tomorrow.

How were Fate Therapeutics Inc’s earnings last quarter?

Fate Therapeutics Inc released its earnings results on May 13, 2026. The company reported -€0.226 earnings per share for the quarter, beating the consensus estimate of -€0.243 by €0.017.

Is Fate Therapeutics Inc overvalued?

According to Wall Street analysts Fate Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Fate Therapeutics Inc pay dividends?

Fate Therapeutics Inc does not currently pay dividends.

What is Fate Therapeutics Inc’s EPS estimate?

Fate Therapeutics Inc’s EPS estimate is -0.23.

How many shares outstanding does Fate Therapeutics Inc have?

Fate Therapeutics Inc has 116,559,190 shares outstanding.

What happened to Fate Therapeutics Inc’s price movement after its last earnings report?

Fate Therapeutics Inc reported an EPS of -€0.226 in its last earnings report, beating expectations of -€0.243. Following the earnings report the stock price went up 2.807%.

Which hedge fund is a major shareholder of Fate Therapeutics Inc?

Currently, no hedge funds are holding shares in DE:F6T

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Fate Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-28.53%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Fate Therapeutics Inc

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.

Fate Therapeutics (F6T) Earnings & Revenues

Historic Earnings Reports

F6T Stock 12 Month Forecast

Average Price Target

€4.55

▲(112.80% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","3":"€3","5":"€5","7":"€7","-1":"-€1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6.94871504,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€6.95</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.5538900351428575,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€4.55</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.9108966360000001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€1.91</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1,3,5,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.232,2.594824233846154,2.957648467692308,3.3204727015384616,3.6832969353846154,4.046121169230769,4.408945403076923,4.771769636923077,5.134593870769231,5.4974181046153845,5.860242338461538,6.223066572307692,6.585890806153846,{"y":6.94871504,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.232,2.41060692578022,2.58921385156044,2.76782077734066,2.9464277031208796,3.1250346289010995,3.303641554681319,3.482248480461539,3.6608554062417586,3.8394623320219785,4.018069257802198,4.196676183582418,4.375283109362638,{"y":4.5538900351428575,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.232,2.2072997412307696,2.1825994824615385,2.157899223692308,2.133198964923077,2.1084987061538465,2.0837984473846154,2.0590981886153847,2.034397929846154,2.0096976710769234,1.9849974123076926,1.9602971535384617,1.935596894769231,{"y":1.9108966360000001,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.927,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.895,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.032,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.158,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.933,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.817,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.937,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.178,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.019,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.27,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.27,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.232,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >